New drug combo targets rare lung tumor gene defect
NCT ID NCT06333951
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 36 times
Summary
This early-stage trial is testing a new drug called anvumetostat, alone or with other cancer drugs, in about 49 adults with advanced lung or chest tumors that lack a gene called MTAP. The main goals are to find the safest dose and to see what side effects occur. Researchers will also check if the tumors shrink or stop growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Adana Sehir Egitim ve Arastirma Hastanesi
Adana, 01370, Turkey (Türkiye)
-
Aichi Cancer Center
Nagoya, Aichi-ken, 464-8681, Japan
-
Alexandra Hospital
Athens, 11528, Greece
-
Ankara Bilkent Sehir Hastanesi
Ankara, 06800, Turkey (Türkiye)
-
Asan Medical Center
Seoul, 05505, South Korea
-
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
Milan, 20162, Italy
-
Beijing Cancer Hospital
Beijing, 100142, China
-
Beneficencia Portuguesa de Sao Paulo - Bp
São Paulo, São Paulo, 01509-900, Brazil
-
Cemic
Ciudad Autonoma Buenos Aires, C1431FWO, Argentina
-
Centre Hospitalier Universitaire de Liege - Sart Tilman
Liège, 4000, Belgium
-
Centro Ricerche Cliniche Di Verona Societa responsabilita limitata
Verona, 37126, Italy
-
Centrum Medyczne Hope Clinic Sebastian Szklener
Lublin, 20-701, Poland
-
Cipo - Centro Integrado de Pesquisa em Oncologia
Porto Alegre, Rio Grande do Sul, 91350-200, Brazil
-
City of Hope National Medical Center
Duarte, California, 91010, United States
-
City of Hope Orange County Lennar Foundation Cancer Center
Duarte, California, 91010, United States
-
Comprehensive Blood and Cancer Center
Bakersfield, California, 93309, United States
-
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89169, United States
-
Eastern Connecticut Hematology and Oncology Associates
Norwich, Connecticut, 06360, United States
-
European Interbalkan Medical Center
Thessaloniki, 57001, Greece
-
Fondazione IRCCS Istituto Nazionale dei Tumori
Alessandria, 15100, Italy
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Fund Faculdade Regional Med Sao Jose Rio Preto
São José do Rio Preto, São Paulo, 15090-000, Brazil
-
Futuremeds spolka z ograniczona odpowiedzialnoscia
Krakow, 31-501, Poland
-
General Hospital Of Thessaloniki Papageorgiou
Thessaloniki, 56429, Greece
-
Guangdong Provincial Peoples Hospital
Guangzhou, Guangdong, 510000, China
-
Gustave Roussy
Villejuif, 94805, France
-
Hacettepe Universitesi Tip Fakultesi Hastanesi
Ankara, 06230, Turkey (Türkiye)
-
HealthPartners Institute
Saint Paul, Minnesota, 55102, United States
-
Hightower Clinical
Oklahoma City, Oklahoma, 73102, United States
-
Hopital de la Timone
Marseille, 13005, France
-
Hospital Clinic i Provincial de Barcelona
Barcelona, Catalonia, 08036, Spain
-
Hospital Universitari Vall d Hebron
Barcelona, Catalonia, 08035, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Austral
Pilar, Buenos Aires, B1629ODT, Argentina
-
IRCCS Istituto Clinico Humanitas
Rozzano (MI), 20089, Italy
-
Institut Bergonie
Bordeaux, 33000, France
-
Institut de Cancerologie de l Ouest Rene Gauducheau
Saint-Herblain, 44805, France
-
Instituto Argentino de Diagnóstico y Tratamiento
Ciudad Automona de Buenos Aires, Buenos Aires, C1117ABC, Argentina
-
Instituto Cancer Sao Paulo Icesp
São Paulo, 01246-000, Brazil
-
Instytut Centrum Zdrowia Matki Polki
Lodz, 93-338, Poland
-
Jilin Cancer Hospital
Changchun, Jilin, 130012, China
-
Medizinische Universitaet Graz
Graz, 8036, Austria
-
Medizinische Universitaet Innsbruck
Innsbruck, 6020, Austria
-
Mengchao Hepatobiliary Hospital of Fujian Medical University
Fuzhou, Fujian, 350028, China
-
Narodowy Instytut Onkologii im Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
Gliwice, 44-102, Poland
-
National Cancer Center Hospital East
Kashiwa-shi, Chiba, 277-8577, Japan
-
National Cheng Kung University Hospital
Tainan, 70403, Taiwan
-
New York University Grossman School of Medicine
New York, New York, 10016, United States
-
Northwest Medical Specialties, PLLC
Tacoma, Washington, 98405, United States
-
Oncology Consultants Cancer Center
Houston, Texas, 77030, United States
-
Oncosite Centro de Pesquisa Clinica Em Oncologia Ltda
Ijuí, Rio Grande do Sul, 98700-000, Brazil
-
Orange Health Service
Orange, New South Wales, 2800, Australia
-
Perlmutter Cancer Center at New York University Langone Hospital----Long Island
New York, New York, 10016, United States
-
Prince of Wales Hospital, Chinese University of Hong Kong
Shatin, New Territories, Hong Kong
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
-
Queen Mary Hospital, The University of Hong Kong
Hong Kong, Hong Kong
-
Radboud Universitair Medisch Centrum
Nijmegen, 6525 GA, Netherlands
-
Rocky Mountain Cancer Centers
Denver, Colorado, 80218, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 32224, United States
-
Saint Lukes Hospital of Kansas City
Kansas City, Missouri, 64111, United States
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Shizuoka Cancer Center
Sunto-gun, Shizuoka, 411-8777, Japan
-
Taipei Veterans General Hospital
Taipei, 11217, Taiwan
-
Texas Oncology - Dallas Fort Worth
Dallas, Texas, 75246, United States
-
Texas Oncology Northeast Texas
Tyler, Texas, 75702, United States
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450052, China
-
The Queen Elizabeth Hospital
Woodville South, South Australia, 5011, Australia
-
Translational Research in Oncology US Inc, Trio Central Pharmacy
Los Angeles, California, 90095, United States
-
US Oncology Research Investigational Products Center
Dallas, Texas, 75246, United States
-
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
-
United States Oncology Regulatory Affairs Corporate Office
Nashville, Tennessee, 37203, United States
-
Universitaetsklinikum Essen
Essen, 45147, Germany
-
Universitaetsklinikum Heidelberg
Heidelberg, 69126, Germany
-
Universitaetsklinikum Wuerzburg
Würzburg, 97078, Germany
-
University of California Irvine
Orange, California, 92868-3217, United States
-
University of California Los Angeles
Santa Monica, California, 90404, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15232, United States
-
University of Tennessee Medical Center Knoxville
Knoxville, Tennessee, 37920, United States
-
Uniwersyteckie Centrum Kliniczne
Gdansk, 80-214, Poland
-
Upstate University Hospital
Syracuse, New York, 13210, United States
-
Virginia Cancer Specialists PC
Fairfax, Virginia, 22031, United States
-
Wakayama Medical University Hospital
Wakayama, Wakayama, 641-8510, Japan
-
West China Hospital Sichuan University
Chengdu, Sichuan, 610041, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Anvumetostat (AMG 193) alone or with carboplatin, paclitaxel, pembrolizumab, pemetrexed, or sotorasib
What this could lead to
If successful, this could point toward a new treatment option for people with advanced lung or chest tumors that have a specific genetic deletion (MTAP).
What could go wrong
This is an early Phase 1b trial with only 49 participants, so it is primarily testing safety and dosing. It is too early to know if the drug will work, and side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.